Stocksigma LogoStocksigma Logo

Alivus Life Sciences Acquires Controlling 65.01% Stake in IQGEN-X Pharma

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has initiated the closing of its Share Purchase Agreement to acquire a 76% stake in

Alivus Life Sciences Acquires Controlling 65.01% Stake in IQGEN-X Pharma

Alivus Life Sciences Ltd 路 Others (Uncategorized) 路 11 Nov 2026, 11:58 pm

Alivus Life Sciences Acquires Controlling 65.01% Stake in IQGEN-X Pharma Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has initiated the closing of its Share Purchase Agreement to acquire a 76% stake in IQGEN-X Pharma Private Limited. As of 11th Nov'26, the company acquired 7,36,096 equity shares, representing a 65.01% paid-up equity stake, making IQGEN-X a subsidiary. The remaining stake up to 76% will be acquired in due course.

Original exchange filing (PDF)

More announcements from Alivus Life Sciences Ltd

All Alivus Life Sciences Ltd announcements